Join to View Full Profile
1 Health PlazaEast Hanover, NJ 07936
Phone+1 856-261-0153
Dr. Mookerjee is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1991 - 1994
ArMed Forces Medical College PuneClass of 1987
Certifications & Licensure
PA State Medical License 2001 - 2024
MD State Medical License 1994 - 2003
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2015-2016
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Clinical Trials
- Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation Start of enrollment: 2000 Oct 01
- Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Start of enrollment: 2000 Jan 01
- AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. Start of enrollment: 2007 Mar 01
Publications & Presentations
PubMed
- 42 citationsCanakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemo...Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho
Lung Cancer. 2024-03-01 - 55 citationsLong-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean-Jacques Grob, Antoni Ribas
European Journal of Cancer. 2020-01-01 - 42 citationsDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 ...G V Long, K T Flaherty, D Stroyakovskiy, H Gogas, E Levchenko
Annals of Oncology. 2019-11-01
Press Mentions
Two Combination Therapies Shrink Melanoma Brain Metastases in More Than Half of PatientsJune 4th, 2017
Two Combination Therapies Shrink Melanoma Brain Metastases in More Than Half of PatientsJune 4th, 2017
Professional Memberships
- Member
- European Society of Medical OncologyMember
Other Languages
- Bengali
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
